XML 40 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Segment Information
 12 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Segment Information
13. Segment Information
Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.
Revenue
Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and repackages generic pharmaceuticals and over-the-counter healthcare products.
Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and
other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.
The following table presents revenue for each reportable segment and Corporate:
(in millions)202320222021
Pharmaceutical$190,009 $165,491 $145,796 
Medical15,014 15,887 16,687 
Total segment revenue205,023 181,378 162,483 
Corporate (1)(11)(14)(16)
Total revenue$205,012 $181,364 $162,467 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following table presents revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:
(in millions)202320222021
Pharmaceutical and Specialty Pharmaceutical Distribution and Services (1)$188,812 $164,580 $144,988 
Nuclear and Precision Health Solutions (2)1,197 911 808 
Pharmaceutical segment revenue
190,009 165,491 145,796 
Medical Products and Distribution (3)12,374 13,462 14,485 
Cardinal Health at-Home Solutions2,640 2,425 2,202 
Medical segment revenue
15,014 15,887 16,687 
  Total segment revenue205,023 181,378 162,483 
Corporate (4)(11)(14)(16)
Total revenue$205,012 $181,364 $162,467 
(1)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.
(2)Increase from prior year relates to new product launches and changes in revenue presentation from agent to principal for certain customer contracts.
(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.
(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

The following table presents revenue by geographic area:
(in millions)202320222021
United States$200,384 $176,855 $157,756 
International4,639 4,523 4,727 
Total segment revenue205,023 181,378 162,483 
Corporate (1)(11)(14)(16)
Total revenue$205,012 $181,364 $162,467 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit
We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology, legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.
We do not allocate the following items to our segments:
•last-in first-out, or ("LIFO"), inventory charges/(credits);
•surgical gown recall costs/(income);
•shareholder cooperation agreement costs;
•state opioid assessment related to prior fiscal years; in connection with the New York Opioid Stewardship Act as discussed further in Note 7;
•restructuring and employee severance;
•amortization and other acquisition-related costs;
•impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in Note 4, we recognized cumulative pre-tax goodwill impairment charges of $1.2 billion and $2.1 billion during fiscal 2023 and 2022, respectively;
•litigation (recoveries)/charges, net; in connection with the opioid litigation as discussed further in Note 7, we recognized a pre-tax charge of $1.17 billion during fiscal 2021;
•other (income)/expense, net;
•interest expense, net;
•loss on early extinguishment of debt;
•(gain)/loss on sale of equity interest in naviHealth;
•provision for/(benefit from) income taxes
In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $35 million, $50 million and $27 million for fiscal 2023, 2022 and 2021, respectively.
The following table presents segment profit by reportable segment and Corporate:
(in millions)202320222021
Pharmaceutical$1,999 $1,770 $1,684 
Medical111 216 577 
Total segment profit2,110 1,986 2,261 
Corporate(1,383)(2,582)(1,789)
Total operating earnings/(loss)$727 $(596)$472 

The following tables present depreciation and amortization and additions to property and equipment by reportable segment and Corporate:
(in millions)202320222021
Pharmaceutical$225 $193 $151 
Medical213 216 226 
Corporate254 283 406 
Total depreciation and amortization$692 $692 $783 

(in millions)202320222021
Pharmaceutical$90 $79 $55 
Medical209 140 97 
Corporate182 168 248 
Total additions to property and equipment$481 $387 $400 
The following table presents total assets for each reportable segment and Corporate at June 30:
(in millions)202320222021
Pharmaceutical$28,077 $26,409 $23,624 
Medical (1) (2)10,130 11,632 15,408 
Corporate5,210 5,837 5,421 
Total assets$43,417 $43,878 $44,453 
(1)Assets of $1.1 billion related to the Cordis business were included within Medical at June 30, 2021. We sold the Cordis business during fiscal 2022.
(2)Medical reflects $1.2 billion and $2.1 billion cumulative pre-tax goodwill impairment charges recorded in connection with the goodwill impairment testing for the Medical Unit during fiscal 2023 and 2022, respectively.

The following table presents property and equipment, net by geographic area:
(in millions)202320222021
United States$2,026 $1,976 $1,958 
International436 385 402 
Property and equipment, net$2,462 $2,361 $2,360